Open AccessH2S as a potential defense against COVID-19?
Author(s) -
Guangdong Yang
Publication year - 2020
Publication title -
american journal of physiology. cell physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.432
H-Index - 181
eISSN - 1522-1563
pISSN - 0363-6143
DOI - 10.1152/ajpcell.00187.2020
Subject(s) - coronavirus , tmprss2 , inflammation , pneumonia , immunology , immune system , medicine , lung , covid-19 , virology , disease , infectious disease (medical specialty)
The outbreak of COVID-19 pneumonia caused by a new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is posing a global health emergency and has led to more than 380,000 deaths worldwide. The cell entry of SARS-CoV-2 depends on two host proteins angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). There is currently no vaccine available and also no effective drug for the treatment of COVID-19. Hydrogen sulfide (H 2 S) as a novel gasotransmitter has been shown to protect against lung damage via its anti-inflammation, antioxidative stress, antiviral, prosurvival, and antiaging effects. In light of the research advances on H 2 S signaling in biology and medicine, this review proposed H 2 S as a potential defense against COVID-19. It is suggested that H 2 S may block SARS-CoV-2 entry into host cells by interfering with ACE2 and TMPRSS2, inhibit SARS-CoV-2 replication by attenuating virus assembly/release, and protect SARS-CoV-2-induced lung damage by suppressing immune response and inflammation development. Preclinical studies and clinical trials with slow-releasing H 2 S donor(s) or the activators of endogenous H 2 S-generating enzymes should be considered as a preventative treatment or therapy for COVID-19.